The Postpartum Depression Drug Market is estimated to be valued at Us$ 6.65 Bn in 2023 and is expected to exhibit a CAGR Of 30% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Postpartum depression refers to a mood disorder that affects women after childbirth. It involves feelings of extreme sadness, anxiety, and exhaustion that may interfere with daily activities and caring of the newborn baby. The drugs used for treatment of postpartum depression work to balance the maternal brain chemistry and relieve symptoms like sadness, tension, irritability, anxiety, and fatigue. Some common classes of drugs used are antidepressants such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and others.
Market Dynamics:
The postpartum depression drug market is expected to witness significant growth owing to the rising incidence of postpartum depression cases across the globe. According to World Health Organization (WHO) reports, over 19% of women in low- and middle-income countries suffer from postpartum depression. Additionally, postpartum psychosis, a severe form of postpartum depression, occurs in about 1-2 women per 1,000 deliveries. Early diagnosis and treatment of postpartum depression are crucial for maternal health and newborn care. Moreover, growing awareness about postpartum mental health issues and increasing availability of treatment options are also expected to boost the market growth over the forecast period. However, adverse effects associated with psychiatric drugs and social stigma related to mental health conditions may hinder the market growth trajectory.
SWOT Analysis
Strength: The increasing awareness about postpartum depression and availability of various treatment options are positively impacting the market growth. Moreover, support from government and healthcare organizations are driving the demand for postpartum depression drugs.
Weakness: High cost and complexities associated with drug development process limits the entry of new players in the market. Adverse effects of few existing drugs hinders their adoption.
Opportunity: Emerging economies with increasing healthcare spending provides lucrative opportunities for market players. Rising adoption of digital therapeutics further opens new windows of growth.
Threats: Patent expiry of blockbuster drugs and introduction of generic versions poses threat to existing players. Stringent regulations for drug approval is a major challenge.
Key Takeaways
The Global Postpartum Depression Drug Market Demand is expected to witness high growth, exhibiting 30% CAGR over the forecast period, due to increasing awareness about mental health issues among women.
Regional analysis
North America dominates the global market and is expected to retain its leading position over the forecast period driven by strong healthcare infrastructure and availability of advanced treatment facilities in the US and Canada. Asia Pacific is anticipated to be the fastest growing region supported by rising healthcare spending, increasing prevalence of postpartum depression, and presence of emerging economies like India and China.
Key players analysis
Key players operating in the Postpartum Depression Drug market are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, AstraZeneca, Johnson & Johnson Private Limited, Bayer AG, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Cipla Inc., Aurobindo Pharma, Lupin, Accord Healthcare, Sun Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Alvogen, Intas Pharmaceuticals Ltd., and SHIONOGI & Co., Ltd.
Get more insights on this topic:
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian